Menu
Search
|

Menu

Close
X

Chembio Diagnostics Inc CEMI.OQ (NASDAQ Stock Exchange Capital Market)

11.20 USD
+0.05 (+0.45%)
As of 3:00 PM BST
chart
Previous Close 11.15
Open 11.10
Volume 1,200
3m Avg Volume 6,870
Today’s High 11.20
Today’s Low 11.10
52 Week High 11.20
52 Week Low 5.75
Shares Outstanding (mil) 12.31
Market Capitalization (mil) 77.55
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
8
FY17
24
FY16
18
FY15
24
EPS (USD)
FY18
-0.049
FY17
-0.518
FY16
-1.299
FY15
-0.249
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
4.21
5.73
Price to Book (MRQ)
vs sector
5.03
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-68.16
14.61
Return on Equity (TTM)
vs sector
-69.09
16.34

EXECUTIVE LEADERSHIP

Katherine Davis
Non-Executive Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
John Sperzel
President, Chief Executive Officer, Director, Since 2017
Salary: $298,558.00
Bonus: --
Neil Goldman
Chief Financial Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Sharon Klugewicz
President - Americas Region, Since 2017
Salary: $259,616.00
Bonus: $75,000.00
Javan Esfandiari
Chief Science and Technology Officer, Since 2015
Salary: $315,000.00
Bonus: $90,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

3661 Horseblock Rd
MEDFORD   NY   11763-2215

Phone: +1631.9241135
Site: chembio.com/

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

SPONSORED STORIES